Clinical trials: Adjuvant Treatment
Ductal Breast Carcinoma In Situ, Early-Stage Breast Carcinoma
Hypofractionated Partial Breast Irradiation in Treating Patients With Early Stage Breast Cancer
This phase II trial studies how well hypofractionated partial breast irradiation works in treating patients with early stage breast cancer.
- Conditions
- Ductal Breast Carcinoma In Situ, Early-Stage Breast Carcinoma, Invasive Breast Carcinoma, Stage 0 Breast Cancer AJCC v6 and v7
- Trial name
- NCT03077841
- Testing
- Laboratory Biomarker Analysis, Partial Breast Irradiation, Questionnaire Administration
- Where
- 15 sites in United States
- Volunteers
- 928 people
- Sponsor
- M.D. Anderson Cancer Center
Triple Negative Breast Neoplasms
Adjuvant Treatment for High-risk Triple Negative Breast Cancer Patients With the Anti-PD-l1 Antibody Avelumab
Phase III randomized trial of the anti-PD-L1 antibody avelumab as adjuvant or post-neoadjuvant treatment for high-risk triple negative breast cancer patients.
- Trial name
- A-Brave (NCT02926196)
- Testing
- MSB0010718C
- Where
- 70 sites in Italy, United Kingdom
- Volunteers
- 474 people
- Sponsor
- Istituto Oncologico Veneto IRCCS
Head and Neck Neoplasms
Porfiromycin Used as an Adjuvant to Radiation Therapy in Postoperative Head and Neck Cancer Patients
Determination of efficacy and safety of porfiromycin versus placebo as an adjuvant to radiotherapy in postoperative head and neck a cancer patients as well as assessment of population pharmacokinetic parameters.
- Trial name
- NCT02183246
- Testing
- Porfiromycin, Radiotherapy
- Volunteers
- 3 people
- Sponsor
- Boehringer Ingelheim
Colon Cancer
A Study of Palifermin for the Reduction of Oral Mucositis in Subjects With Stage 2B or 3 Locally Advanced, Colon Cancer
The purpose of this study is to evaluate the efficacy, safety, and tolerability of palifermin (recombinant human keratinocyte growth factor, rHuKGF) in reducing the incidence of oral mucositis in subjects with stage 2B and 3…
- Trial name
- NCT00393822
- Testing
- palifermin
- Volunteers
- 100 people
- Sponsor
- Amgen
Melanoma
A Study to Evaluate Similarity of ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Resected Melanoma
The purpose of this study is to investigate the pharmacokinetic (PK) similarity and efficacy, safety, and immunogenicity of ABP 206 compared with OPDIVO® (nivolumab) in subjects with resected advanced melanoma.
- Trial name
- NCT05907122
- Testing
- ABP 206, FDA-licensed Nivolumab, EU-authorized Nivolumab
- Where
- 76 sites in United States, Argentina and 20 more
- Volunteers
- 256 people
- Sponsor
- Amgen
Breast Cancer
Combination Chemotherapy With or Without Colony-stimulating Factors in Treating Women With Breast Cancer
RATIONALE: 1. . To compare the effects on breast cancer of three different combinations of drugs which are commonly used to treat this disease. 2. . It is not yet known which treatment regimen is most effective for breast cancer.
- Trial name
- NCT00014222
- Testing
- epoetin alfa, filgrastim, cyclophosphamide
- Where
- 78 sites in United States, Canada
- Volunteers
- 2,104 people
- Sponsor
- NCIC Clinical Trials Group
Breast Cancer
Delayed Adjuvant Herceptin® Treatment in Patients With HER-2 Positive Breast Cancer
The purpose of the study is to determine what factors affect a patient's decision to accept delayed Herceptin® treatment after completing their surgery and/or chemotherapy and/or radiation therapy.
- Trial name
- NCT00427427
- Testing
- Trastuzumab
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Stage ⅠA Pancreatic Cancer, Stage ⅠB Pancreatic Cancer
Second-Line Adjuvant Therapy With Nab-Paclitaxel Plus Gemcitabine Versus Oxaliplatin Plus Folinic Acid and Fluorouracil for Gemcitabine-Refractory Pancreatic Cancer After Curative Resection
The purpose of this study is to investigate the activity and safety of second-line adjuvant therapy with nab-paclitaxel plus gemcitabine (AG) versus oxaliplatin plus folinic acid and fluorouracil (OFF) for gemcitabine-refractory…
- Conditions
- Stage ⅠA Pancreatic Cancer, Stage ⅠB Pancreatic Cancer, Stage ⅡA Pancreatic Cancer, Stage ⅡB Pancreatic Cancer
- Trial name
- NCT02506842
- Testing
- nab-paclitaxel, gemcitabine, oxaliplatin
- Where
- 7 sites in China
- Volunteers
- 300 people
- Sponsor
- Fudan University
Breast Cancer, Adjuvant Therapy
Compare Continuation of Original Targeted Therapy With Trastuzumab Combined With Pyrotinib and Capecitabine as Postoperative Adjuvant Therapy in Non-pCR Patients With HER2 Positive Early Breast Cancer
To evaluate the efficacy of continuation targeted therapy compared with trastuzumab combined with Pyrotinib and capecitabine in postoperative adjuvant therapy of HER-2 positive early breast cancer patients with residual tumor…
- Trial name
- NCT05292742
- Testing
- Pyrotinib+Trastuzumab+Capecitabine, Trastuzumab+Pertuzumab/Trastuzumab
- Where
- China
- Volunteers
- 206 people, healthy volunteers welcome
- Sponsor
- Fujian Medical University Union Hospital
Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter
Combination Chemotherapy Following Surgery in Treating Patients With Urinary Tract Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00028860
- Testing
- filgrastim, carboplatin, gemcitabine hydrochloride
- Where
- United States
- Sponsor
- Tulane University Health Sciences Center
Colorectal Neoplasms, Liver Neoplasms
Comparing Irinotecan and 5 FU/FA To 5-FU/FA After Resection Of Liver Metastases For Colorectal Cancer
To see if Disease Free Survival (DFS) is improved when complete surgical resection of liver metastases (R0) is followed by chemotherapy with CPT-11 and 5-FU/FA as FOLFIRI regimen, compared to 5-FU/FA alone.
- Trial name
- NCT00143403
- Testing
- Irinotecan + 5 FU + folinic acid, Folinic Acid + 5 FU
- Where
- 66 sites in Belgium, Denmark and 14 more
- Volunteers
- 321 people
- Sponsor
- Pfizer
Metastases
Evaluation of Adjuvant Hormonal Treatment for 24 Months After Radical Prostatectomy in High Risk of Recurrence Patients.
PRINCIPAL OBJECTIVE: Evaluation of effectiveness in terms of survival without metastases to 10 years, of adjuvant hormonal treatment with leuprorelin acetate (Eligard® 45 mg) for 24 months after radical prostatectomy in patients…
- Trial name
- NCT01442246
- Testing
- Leuprorelin Acetate
- Where
- 35 sites in France
- Volunteers
- 700 people
- Sponsor
- UNICANCER
Prostate Cancer
A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation
The purpose of the study is to demonstrate superiority of Saruparib (AZD5305) relative to placebo added to a standard radiation therapy (RT) + androgen deprivation therapy (ADT) regimen by assessment of metastases-free survival…
- Trial name
- EvoPAR-PR02 (NCT06952803)
- Testing
- Saruparib, Abiraterone + Prednisolone/Prednisone, Androgen Deprivation Therapy (ADT)
- Where
- 346 sites in United States, Argentina and 26 more
- Volunteers
- 700 people
- Sponsor
- AstraZeneca
Neoplasms, Breast
Safety and Immunogenicity Study of the New dHER2 Vaccine to Treat HER2-positive Metastatic Breast Cancer
Patients will receive a maximum of 18 injections of dHER2 vaccine in a treatment schedule that will last for up to about a year, and thereafter there will be a follow-up period of about one more year.
- Trial name
- NCT00140738
- Testing
- GSK Biologicals' 719125
- Where
- 14 sites in Belgium, Colombia and 3 more
- Volunteers
- 3 people
- Sponsor
- GlaxoSmithKline
Sarcoma
Study of Preoperative RAdiation Therapy With Concomitant Liposomal Transcrocetin (L-TC) in Soft tISsue Sarcomas
This is phase II randomized, multicenter study of treatment with L-TC and preoperative HFRT in patients who were aged 18 years or older with documented localised or locally advanced soft-tissue sarcoma of the extremity.
- Trial name
- PRACTISS (NCT06476704)
- Testing
- Administration of L-TC, HFRT alone
- Where
- 2 sites in France
- Volunteers
- 42 people
- Sponsor
- Centre Paul Strauss
Pancreatic Neuroendocrine Tumor G2
Real-world Study on Adjuvant Octreotide Therapy in pNETs
Adjuvant therapy in pancreatic neuroendocrine tumors (pNETs) after radical resection lacks evidence-based data and is controversial.
- Trial name
- NCT06080204
- Testing
- Octreotide LAR
- Volunteers
- 411 people
- Sponsor
- Changhai Hospital
Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
Phase 2 Study of Trastuzumab Deruxtecan in the Neoadjuvant Treatment, or Trastuzumab Deruxtecan Plus Capecitabine Plus Durvalumab(MEDI4736) in the Preoperative and Postoperative Adjuvant Treatment for Patients With HER2 Positive Gastric and Gastroesophageal Junction Adenocarcinoma
This study is an open-label, single-arm, multicenter, Phase 2 study to evaluate the efficacy and safety of neoadjuvant chemotherapy with T-DXd monotherapy in patients with HER2-positive gastric cancer.
- Trial name
- NCT05034887
- Testing
- Trastuzumab Deruxtecan (T-DXd) monotherapy, T-DXd, Durvalumab and Capecitabine Combination
- Where
- Japan
- Volunteers
- 64 people
- Sponsor
- National Cancer Center Hospital East
Solid Tumor
Evaluationn of Tolerability and Safety of CBT101, an Autologous Natural Killer Cell, in Patients With Solid Cancer
The objective of the study is to evaluate tolerability and safety of CBT101 in patients who underwent curative surgery and adjuvant therapy for solid cancer
- Trial name
- NCT04557306
- Testing
- CBT101 cells, every 2 weeks, CBT101 cells, every 4 weeks
- Where
- South Korea
- Volunteers
- 6 people
- Sponsor
- CHABiotech CO., Ltd
Prostate Cancer
Adjuvant Treatment of Prostate Cancer With Docetaxel or Not After Radical Radiotherapy
As docetaxel is proven to be effective in late stages of prostate cancer with a large tumour burden it should be effective in primarily treated intermediate and high risk prostate cancer as an adjuvant treatment after…
- Trial name
- AdRad (NCT00653848)
- Testing
- docetaxel
- Where
- Norway
- Volunteers
- 378 people
- Sponsor
- Scandinavian Prostate Cancer Group
Biliary Tract Cancer
Phase I Study of Gemcitabine or S-1 Adjuvant Therapy After Hemihepatectomy for Biliary Tract Cancer
To decide maximum tolerated dose and/or recommended dose of Gemcitabine or S-1 adjuvant therapy after hemihepatectomy
- Trial name
- NCT01291615
- Testing
- Gemcitabine, S-1
- Where
- Japan
- Volunteers
- 6 people
- Sponsor
- Kansai Hepatobiliary Oncology Group
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.